Objective: Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive occlusion of the internal carotid artery and the secondary formation of collateral vessels. Patients with MMD have ischemic attacks or intracranial bleeding, but the disease pathophysiology remains unknown. In this study, the authors aimed to identify a gene expression profile specific to the intracranial artery in MMD.
Methods: This was a single-center, prospectively sampled, retrospective cohort study. Microsamples of the middle cerebral artery (MCA) were collected from patients with MMD (n = 11) and from control patients (n = 9). Using microarray techniques, transcriptome-wide analysis was performed.
Results: Comparison of MCA gene expression between patients with MMD and control patients detected 62 and 26 genes whose expression was significantly (p < 0.001 and fold change > 2) up- or downregulated, respectively, in the MCA of MMD. Gene set enrichment analysis of genes expressed in the MCA of patients with MMD revealed positive correlations with genes involved in antigen processing and presentation, the dendritic cell pathway, cytokine pathway, and interleukin-12 pathway, and negative correlations with genes involved in oxidative phosphorylation and DNA repair. Microarray analysis was validated by quantitative polymerase chain reaction.
Conclusions: Transcriptome-wide analysis showed upregulation of genes for immune responses and downregulation of genes for DNA repair and oxidative phosphorylation within the intracranial artery of patients with MMD. These findings may represent clues to the pathophysiology of MMD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3171/2021.6.FOCUS20870 | DOI Listing |
Objectives: To evaluate the treatment effects of the modified miniscrew-assisted rapid palatal expander (MARPE) and rapid palatal expander (RPE) with distalizers in patients with Class II malocclusion and maxillary crowding.
Materials And Methods: The sample comprised 28 skeletal Class I adolescents with dental Class II malocclusion and maxillary crowding of >4 mm who received nonextraction treatment. Fourteen patients were treated with a modified MARPE with distalizer (MMD), while another 14 patients were treated with a modified RPE with distalizer (MRD).
J Korean Neurosurg Soc
January 2025
Department of Neurosurgery, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
Objective: The leptomeningeal ivy sign is a distinctive finding of moyamoya disease (MMD), characterized by a linear high signal intensity along the cortical sulci on contrast-enhanced T1 magnetic resonance imaging (MRI) and fluid-attenuated inversion-recovery MRI. We recently identified a similar linear enhancement along the cortical sulci using gadolinium-enhanced vessel wall MRI (VWMR) in patients with MMD. The aim of this study was to introduce the concept of the "VWMR ivy sign (VIS)".
View Article and Find Full Text PDFPsychiatry Res
December 2024
the Seventh People's Hospital of Wenzhou, Zhejiang Province, China.
Objective: A proportion of patients with bipolar disorder (BD) manifests with only Unipolar mania (UM). We conducted a follow-up study of patients diagnosed with Unipolar mania and compared them as a group if they had a mild depressive episode with those who did not.
Method: 248 subjects were prospectively followed-up to 15 years.
Acta Neurochir (Wien)
January 2025
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Purpose: Bypass surgery is regarded as the standard treatment option for symptomatic and hemodynamically unstable moyamoya disease (MMD). However, there is ongoing debate about the most effective type of bypass surgery. We aimed to analyze the long-term outcomes of combined and indirect bypasses for MMD patients through intra-individual comparisons.
View Article and Find Full Text PDFAdv Ther
January 2025
Dent Neurologic Institute, 3980 Sheridan Dr., Amherst, NY, 14226, USA.
Introduction: Fremanezumab, a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway, and gepants, small molecule CGRP receptor antagonists, are both approved for the treatment of migraine or its symptoms. This study assessed effectiveness, tolerability, and migraine-related healthcare resource utilization (HCRU) after the addition of fremanezumab for preventive migraine treatment in patients using gepants for acute treatment.
Methods: Data were extracted during a retrospective chart review from electronic medical records from the Dent Neurologic Institute.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!